骨髓增生异常/骨髓增殖性肿瘤伴环状铁粒幼细胞和血小板增多的诊断与治疗

何广胜

doi:10.13201/j.issn.1004-2806.2021.11.003

骨髓增生异常/骨髓增殖性肿瘤伴环状铁粒幼细胞和血小板增多的诊断与治疗

何广胜^,

- 南京医科大学第一附属医院, 江苏省人民医院血液科(南京, 210029)

详细信息

通讯作者: 何广胜,E-mail:heguangsheng1972@sina.com

中图分类号: R733.3

收稿日期: 2021-08-30

Diagnosis and treatment of myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis

HE Guangsheng^,

More Information

Corresponding author: HE Guangsheng, E-mail: heguangsheng1972@sina.com

Received Date: 30 August 2021

摘要

- 骨髓增生异常综合征 /
- 骨髓增殖性肿瘤 /
- 环状铁粒幼细胞 /
- 血小板增多 /
- SF3B1
- myelodysplastic syndrome /
- myeloproliferative neoplasm /
- ring sideroblasts /
- thrombocythemia /
- SF3B1

HTML全文

参考文献(14)

[1]	Arber DA, Orazi A, Hasserjian R, et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J].Blood, 2016, 127(20):2391-2405.
[2]	朱雨, 何广胜.世界卫生组织2016年骨髓增殖性肿瘤及骨髓增生异常综合征/骨髓增殖性肿瘤分类更新解读[J].中国实用内科杂志, 2016, 36(8):658-661.
[3]	Patnaik MM, Lasho TL.Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlapsyndromes[J].Hematology Am Soc Hematol Educ Program, 2020, 2020(1):450-459.
[4]	Patnaik MM, Tefferi A.Refractory Anemia with Ring Sideroblasts(RARS) and RARS with Thrombocytosis(RARS-T):"2019 Update on Diagnosis, Risk-stratification, and Management"[J].Am J Hematol, 2019, 94(4):475-488.
[5]	Jeromin S, Haferlach T, Weissmann S, et al.Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations[J].Haematologica, 2015, 100(4):e125-e127.
[6]	Patnaik MM, Lasho TL, Finke CM, et al.Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis(RARS-T) and the role of next-generation sequencing[J].Am J Hematol, 2016, 91(5):492-498.
[7]	Fenaux P, Platzbecker U, Mufti GJ, et al.Luspatercept in patients with lower-risk myelodysplastic syndromes[J].N Engl J Med, 2020, 382(2):140-151.
[8]	周炯涛, 何广胜.SF3B1突变型骨髓增生异常综合征亚型发病机制及诊断[J].中国实用内科杂志, 2021, 41(1):27-29.
[9]	何广胜.机制导向治疗——地西他滨治疗骨髓增生异常综合征[J].中国实用内科杂志, 2015, 35(2):126-128.
[10]	Jabbour E, Short NJ, Montalban-Bravo G, et al.Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN[J].Blood, 2017, 130(13):1514-1522.
[11]	方宝枝, 潘金兰, 刘丹丹, 等.骨髓增生异常综合征-难治性中性粒细胞减少1例及文献复习[J].临床血液学杂志, 2011, 24(3):139-141.
[12]	刘真真, 何广胜, 吴德沛, 等.减低剂量的地西他滨治疗骨髓增生异常综合征-难治性血小板减少[J].临床血液学杂志, 2013, 26(3):165-167.
[13]	方宝枝, 刘真真, 何广胜, 等.减低剂量地西他滨对输血依赖性低危骨髓增生异常综合征的临床疗效[J].中华医学杂志, 2013, 93(40):3189-3192.
[14]	Patnaik MM, Lasho TL, Finke CM, et al.Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis[J].Leukemia, 2016, 30(11):2273-2275.